GLUE
Monte Rosa Therapeutics Inc
11.80$
+0.4%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | -87.8% | +341.3% | +96.3% | +558.1% | +40.0% | -72.7% | -45.0% | -78.2% | +51.4% | +113.0% | – | |
| – | +0.7% | +2.8% | +8.6% | +2.1% | -2.0% | – | – | -1.4% | -0.3% | -2.8% | – | – | |
| – | – | – | – | +249.8% | +558.1% | +40.0% | -72.7% | -45.0% | -78.2% | -21.6% | +311.2% | – | |
| – | -4.1% | -7.4% | +3.4% | +6.2% | +40.7% | -17.2% | -4.8% | +19.7% | +14.5% | +5.0% | +8.8% | – | |
| – | -10.8% | +16.3% | +3.3% | -12.4% | +8.0% | -0.8% | -7.0% | +12.0% | +16.0% | -3.3% | -0.4% | – | |
| – | -5.7% | -2.1% | +3.4% | +1.3% | +33.3% | -14.2% | -5.2% | +18.1% | +14.8% | -0.5% | +11.3% | – | |
| – | – | – | – | – | – | +238.6% | -135.3% | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | +205.8% | -123.3% | – | – | – | – | – | |
| – | -112.9% | – | +203.6% | -71.8% | +2,947.9% | -62.0% | +45.9% | -365.0% | – | -11.9% | +300.0% | – | |
| – | – | – | – | – | – | +248.9% | -126.2% | – | – | – | – | – | |
| – | – | – | – | – | – | +181.7% | -118.0% | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.